I, the subject of personal data (a visitor to the official website of NovaMedica LLC on the Internet information and telecommunication network https://novamedica.com/ru), in reliance on Article 9 of Federal Law No. 152-ФЗ dated July 27, 2006 on Personal Data, acting of my own free will and in my own interest, hereby voluntarily provide my personal data and give my consent to NovaMedica Limited Liability Company (Taxpayer’s Individual Number 7718886050), registered in accordance with the legislation of the Russian Federation at: 125124, 18, 3rd Yamskogo Polya street, Moscow, (hereinafter, the “Organization”), to the processing of my personal data upon the following conditions:
1. This Consent is given to the processing of my personal data using automation tools. This Consent is given to the processing of my following personal data: full name (last name, first name, patronymic); phone number; email address; CV; cookie files (user data (location, OS type and version, browser type and version, device type and screen resolution; source from where the user came to the website (website or advertisement); OS and browser language ; pages that the user opens and buttons that the user clicks; IP address); information about me that will become known during performance of contracts (if a contract will be executed between me and the Organization), as well as other publicly available information about me.
2. Purposes of personal data processing: sending a response to a website visitor’s message (processing incoming messages from individuals with the purpose of providing consultations on various issues related to the Organization’s field of activity); considering a suitable candidate for employment; analyzing the actions of an individual on the website and the functioning of the website.
3. The basis for the processing of personal data is Article 24 of the Constitution of the Russian Federation; Article 6 of Federal Law No. 152-ФЗ on Personal Data; this Consent of the website visitor to the processing of personal data.
4. During the processing of personal data, the Organization has the right to perform any of the following actions (operations) or a set of the following actions (operations) with personal data: collection, recording, systematization, accumulation, storage, correction (update, modification), extraction, use, transfer (provision, access), blocking, deletion, destruction of personal data.
5. I am hereby notified by the Organization that the intended users of personal data are employees of the Organization, as well as persons engaged by the Organization under civil law contracts.
6. I am aware, that:
6.1. This Consent to the processing of my personal data is valid for 13 months (1 year 1 month) and can be revoked by me sending a notification to the Organization’s email: privacy@novamedica.com.
6.2. I have the right to access my personal data, to request correction (update, modification) of my personal data, as well as deletion and destruction of my personal data in case their processing by the Organization violates my lawful rights and interests or the legislation of the Russian Federation.
6.3. In case of withdrawal of this Consent to the processing of personal data, the Organization has the right to continue processing personal data without consent of the personal data subject in cases provided for by the legislation of the Russian Federation.
7. By giving this Consent, I confirm that I am the subject of the personal data provided, and also confirm the accuracy of the data provided.
8. This Consent is valid until termination of the processing of my personal data in accordance with clause 6.1 of this Consent.
NovaMedica in the TOP-1000 Russian Managers Rating
28 September 2024
06 September 2024
NovaMedica expands its line of products for the treatment of Alzheimer’s disease
22 August 2024
The Ministry of Economic Development predicts a 33.1% increase in medical production by 2027
04 October 2024
Deputy Prime Minister: “Russia helps CIS and African countries with monkeypox diagnostics”
04 October 2024
Optimising wet granulation manufacturing with advanced technologies
03 October 2024
First-in-class therapy approved for schizophrenia
03 October 2024